, Biological actions of cholecystokinin, Peptides, vol.15, issue.4, pp.731-755, 1994.
DOI : 10.1016/0196-9781(94)90104-X
, Direct demonstration of three different states of the pancreatic cholecystokinin receptor., Proceedings of the National Academy of Sciences, vol.91, issue.5, pp.1868-1872, 1994.
DOI : 10.1073/pnas.91.5.1868
, Receptor subtypes or species homologues: relevance to drug discovery, Trends in Pharmacological Sciences, vol.14, issue.10, pp.376-383, 1993.
DOI : 10.1016/0165-6147(93)90096-3
, Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors, Neuroscience & Biobehavioral Reviews, vol.18, issue.2, pp.207-214, 1994.
DOI : 10.1016/0149-7634(94)90025-6
, Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists, Brain Research, vol.572, issue.1-2, pp.208-215, 1992.
DOI : 10.1016/0006-8993(92)90471-K
, The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats, Psychopharmacology, vol.16, issue.2, pp.119-126, 1996.
DOI : 10.1007/BF02246168
, Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist, Biological Psychiatry, vol.28, issue.2, pp.169-173, 1990.
DOI : 10.1016/0006-3223(90)90635-F
, Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors, Science, vol.245, issue.4925, pp.1509-1511, 1989.
DOI : 10.1126/science.2781294
, The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance, Regulatory Peptides, vol.65, issue.1, pp.23-28, 1996.
DOI : 10.1016/0167-0115(96)00068-7
, The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat, European Journal of Pharmacology, vol.176, issue.1, pp.35-44, 1990.
DOI : 10.1016/0014-2999(90)90129-T
, PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes., Proceedings of the National Academy of Sciences, vol.87, issue.18, pp.7105-7109, 1990.
DOI : 10.1073/pnas.87.18.7105
, Cholecystokinin antianalgesia: safety cues abolish morphine analgesia, Science, vol.256, issue.5058, pp.830-833, 1992.
DOI : 10.1126/science.1589765
, Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats, Brain Research, vol.613, issue.2, pp.221-229, 1993.
DOI : 10.1016/0006-8993(93)90902-Y
, Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity, Brain Research, vol.665, issue.2, pp.237-244, 1994.
DOI : 10.1016/0006-8993(94)91343-9
, Blockade of Neurotensin Receptor by SR 48692 Potentiates the Facilitatory Effect of Haloperidol on the Evoked In Vivo Dopamine Release in the Rat Nucleus Accumbens, Journal of Neurochemistry, vol.64, issue.5, pp.2073-2079, 1995.
DOI : 10.1046/j.1471-4159.1995.64052073.x
, Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats, Psychopharmacology, vol.105, issue.2, pp.237-241, 1994.
DOI : 10.1007/BF02245067
, Endogenous Neurotensin Regulates Hypothalamic-Pituitary-Adrenal Axis Activity and Peptidergic Neurons in the Rat Hypothalamic Paraventricular Nucleus, Journal of Neuroendocrinology, vol.9, issue.4, pp.263-269, 1997.
DOI : 10.1046/j.1365-2826.1997.00581.x
, Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?, Trends in Neurosciences, vol.18, issue.1, pp.6-14, 1995.
DOI : 10.1016/0166-2236(95)93942-Q
, A potent nonpeptide antagonist of the substance P (NK1) receptor, Science, vol.251, issue.4992, pp.435-437, 1991.
DOI : 10.1126/science.1703323
, Pharmacological properties of a potent and selective nonpeptide substance P antagonist., Proceedings of the National Academy of Sciences, vol.88, issue.22, pp.10208-10212, 1991.
DOI : 10.1073/pnas.88.22.10208
, Appetite-Suppressing Effects of Urocortin, a CRF-Related Neuropeptide, Science, vol.273, issue.5281, pp.1561-1564, 1996.
DOI : 10.1126/science.273.5281.1561
, Corticotrophin-releasing factor receptors: from molecular biology to drug design, Trends in Pharmacological Sciences, vol.17, issue.4, pp.166-172, 1996.
DOI : 10.1016/0165-6147(96)81594-X
, CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors., Proceedings of the National Academy of Sciences, vol.93, issue.19, pp.10477-10482, 1996.
DOI : 10.1073/pnas.93.19.10477
, The Panicogenic Effects of Cholecystokinin-Tetrapeptide Are Antagonized by L-365,260, a Central Cholecystokinin Receptor Antagonist, in Patients With Panic Disorder, Archives of General Psychiatry, vol.51, issue.6, pp.486-493, 1994.
DOI : 10.1001/archpsyc.1994.03950060050005
, A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder, Biological Psychiatry, vol.37, issue.7, pp.462-466, 1995.
DOI : 10.1016/0006-3223(94)00190-E
, A Double-Blind, Placebo-Controlled Study of a CCK-B Receptor Antagonist, CI-988, in Patients With Generalized Anxiety Disorder, Journal of Clinical Psychopharmacology, vol.15, issue.6, pp.428-434, 1995.
DOI : 10.1097/00004714-199512000-00007
, The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients, Psychopharmacology, vol.31, issue.Suppl., pp.243-248, 1997.
DOI : 10.1007/s002130050186
, Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity, European Journal of Pharmacology, vol.209, issue.1-2, pp.135-138, 1991.
DOI : 10.1016/0014-2999(91)90025-L
, OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist, Science, vol.252, issue.5005, pp.572-574, 1991.
DOI : 10.1126/science.1850553
, Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors., Journal of Clinical Investigation, vol.92, issue.1, pp.224-231, 1993.
DOI : 10.1172/JCI116554
, Endothelin receptors: Receptor classification, novel receptor antagonists, and potential therapeutic targets, Medicinal Research Reviews, vol.16, issue.4, pp.365-390, 1996.
DOI : 10.1002/(SICI)1098-1128(199607)16:4<365::AID-MED4>3.0.CO;2-V
, Frequency-dependent release of peptide cotransmitters from identified cholinergic motor neurons in Aplysia., Proceedings of the National Academy of Sciences, vol.86, issue.22, pp.9034-9038, 1989.
DOI : 10.1073/pnas.86.22.9034
, Neuropeptides in perspective: The last ten years, Neuron, vol.7, issue.6, pp.867-879, 1991.
DOI : 10.1016/0896-6273(91)90333-U
, A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus, Science, vol.230, issue.4722, pp.177-179, 1985.
DOI : 10.1126/science.2994227
, -phenyl-piperidin-3-yl)amine GR205171: (2S-cis)-N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl-[1-adamantane-1-methyl]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1,5- benzodiazepin-3-yl)-N'-phenylurea ICID6888: 2-ethyl-5[2'-{1H-tetrazol-5-yl}biphenyl-4-yl]methoxy)quinoline ICID8731: 2-ethyl-4-([2'-{1H-tetrazol-5-yl}biphenyl-4-yl]methoxy)quinoline KSG504: (S)-arginium(R)-4-[-N-(3-methoxypropyl)-N-pentylcarbamoyl]-5-(2- naphtylsulfonyl)pentanoate monohydrate kuwanon H: [1S-(1a,5a,6b)]-8-[6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4- dihydroxyphenyl)-3-methylcyclohex-2-en-1yl)imidazol[4,5-b]pyridine L161638: N-[2-ethyl-3-,4-dihydro-4-oxo-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl(N,N-diphenylaminocarbonyl)-4-('N',N'-di-n-pentylaminocarbonyl)piperazine-2- diethylaminopropylcarboxamide L163017: 6-(benzoylamino)-7-methyl-2-propyl-3-([2'-{N-(3-methyl-1- butoxy)carbonylaminosulfonyl}(1,1')-biphenyl-4-yl]methyl)-3H-imidazo(4,5-b)pyridine L365031: 1-methyl-3-(4-bromobenzoyl)amino-5-phenyl-3H-1,4-benzodiazepin-2-one L365260, Proc. Natl. Acad. Sci. U.S.A. 83)amino)bicyclo[2.2.1]hept-1- yl)methyl)sulfonyl)spiro(1H-indene-1,4'-piperidine), hydrochloride L368899, pp.4918-4922, 1986.
URL : https://hal.archives-ouvertes.fr/hal-01158298